210 related articles for article (PubMed ID: 38599096)
1. Progress of engineered bacteria for tumour therapy.
Xia X; Zhang JW; Zhao B; Zhang M; Chen ZR; Zhang BF; Ji YL; Wang X; Xiong WM; Li JW; Lv QL
Int Immunopharmacol; 2024 May; 132():111935. PubMed ID: 38599096
[TBL] [Abstract][Full Text] [Related]
2. Bacterially mediated drug delivery and therapeutics: Strategies and advancements.
Wu L; Bao F; Li L; Yin X; Hua Z
Adv Drug Deliv Rev; 2022 Aug; 187():114363. PubMed ID: 35649449
[TBL] [Abstract][Full Text] [Related]
3. Genetically engineered bacteria: a new frontier in targeted drug delivery.
Fooladi S; Rabiee N; Iravani S
J Mater Chem B; 2023 Nov; 11(42):10072-10087. PubMed ID: 37873584
[TBL] [Abstract][Full Text] [Related]
4. Current status of intratumour microbiome in cancer and engineered exogenous microbiota as a promising therapeutic strategy.
Chen J; Li T; Liang J; Huang Q; Huang JD; Ke Y; Sun H
Biomed Pharmacother; 2022 Jan; 145():112443. PubMed ID: 34847476
[TBL] [Abstract][Full Text] [Related]
5. Genetically engineered oncolytic bacteria as drug delivery systems for targeted cancer theranostics.
Chen Y; Liu X; Guo Y; Wang J; Zhang D; Mei Y; Shi J; Tan W; Zheng JH
Acta Biomater; 2021 Apr; 124():72-87. PubMed ID: 33561563
[TBL] [Abstract][Full Text] [Related]
6. Targeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium.
Guo Y; Chen Y; Liu X; Min JJ; Tan W; Zheng JH
Cancer Lett; 2020 Jan; 469():102-110. PubMed ID: 31666180
[TBL] [Abstract][Full Text] [Related]
7. Engineered bacteria in tumor immunotherapy.
Chen H; Zhu Y; Zhang C; Hu L; Yang K
Cancer Lett; 2024 May; 589():216817. PubMed ID: 38492769
[TBL] [Abstract][Full Text] [Related]
8. Tweak to Treat: Reprograming Bacteria for Cancer Treatment.
Sieow BF; Wun KS; Yong WP; Hwang IY; Chang MW
Trends Cancer; 2021 May; 7(5):447-464. PubMed ID: 33303401
[TBL] [Abstract][Full Text] [Related]
9. Bacteria and cancer: Different sides of the same coin.
Laliani G; Ghasemian Sorboni S; Lari R; Yaghoubi A; Soleimanpour S; Khazaei M; Hasanian SM; Avan A
Life Sci; 2020 Apr; 246():117398. PubMed ID: 32032647
[TBL] [Abstract][Full Text] [Related]
10. Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Curr Pharm Des; 2000 Feb; 6(3):261-76. PubMed ID: 10637379
[TBL] [Abstract][Full Text] [Related]
11. Engineered Microorganisms for Advancing Tumor Therapy.
Jia J; Wang X; Lin X; Zhao Y
Adv Mater; 2024 Jun; 36(24):e2313389. PubMed ID: 38485221
[TBL] [Abstract][Full Text] [Related]
12. Ultrasound-controllable engineered bacteria for cancer immunotherapy.
Abedi MH; Yao MS; Mittelstein DR; Bar-Zion A; Swift MB; Lee-Gosselin A; Barturen-Larrea P; Buss MT; Shapiro MG
Nat Commun; 2022 Mar; 13(1):1585. PubMed ID: 35332124
[TBL] [Abstract][Full Text] [Related]
13. Bacteria and bacterial derivatives as delivery carriers for immunotherapy.
Kang SR; Nguyen DH; Yoo SW; Min JJ
Adv Drug Deliv Rev; 2022 Feb; 181():114085. PubMed ID: 34933064
[TBL] [Abstract][Full Text] [Related]
14. Tumour-targeting bacteria engineered to fight cancer.
Zhou S; Gravekamp C; Bermudes D; Liu K
Nat Rev Cancer; 2018 Dec; 18(12):727-743. PubMed ID: 30405213
[TBL] [Abstract][Full Text] [Related]
15. Current advances in bacteria-based cancer immunotherapy.
Guo C; Liu J; Zhang Y
Eur J Immunol; 2024 Feb; 54(2):e2350778. PubMed ID: 38105295
[TBL] [Abstract][Full Text] [Related]
16. Bacteria-Based Cancer Immunotherapy.
Huang X; Pan J; Xu F; Shao B; Wang Y; Guo X; Zhou S
Adv Sci (Weinh); 2021 Apr; 8(7):2003572. PubMed ID: 33854892
[TBL] [Abstract][Full Text] [Related]
17. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
18. The next frontier of oncotherapy: accomplishing clinical translation of oncolytic bacteria through genetic engineering.
Dailey KM; Allgood JE; Johnson PR; Ostlie MA; Schaner KC; Brooks BD; Brooks AE
Future Microbiol; 2021 Mar; 16(5):341-368. PubMed ID: 33754804
[TBL] [Abstract][Full Text] [Related]
19. Genetically Engineered-Cell-Membrane Nanovesicles for Cancer Immunotherapy.
Cheng Q; Kang Y; Yao B; Dong J; Zhu Y; He Y; Ji X
Adv Sci (Weinh); 2023 Sep; 10(26):e2302131. PubMed ID: 37409429
[TBL] [Abstract][Full Text] [Related]
20. Genetically engineered T cells for the treatment of cancer.
Essand M; Loskog AS
J Intern Med; 2013 Feb; 273(2):166-81. PubMed ID: 23198862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
